Filing Flows › Industrials › Alamar Biosciences (ALMR)
Alamar Biosciences (ALMR) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · Alamar Biosciences (ALMR) Q3 2026 earnings results →
Q3 2026 Revenue up 68% year over year to $33.5M · 40¢ of every $1 of revenue lost · operating margin -45.1%
Alamar Biosciences made $33.5M in Q3 2026 (+68% Y/Y): Product $26.3M, Service Other $7.2M. Operating margin -45.1%, net loss $13.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $33.5M in Q3 2026, up 68% year over year and up 14% from the previous quarter. Consumables was the largest line at 53% of revenue. Consumables added $7.9M year over year (up 79%), 58% of the total change.
Gross margin was 61.5%, up 1.8 points from a year earlier. Operating costs exceeded revenue by $15.1M, an operating margin of -45.1%. Operating expenses grew 81% against revenue growth of 68%. The fastest-growing cost line was SG&A (+105%). The quarter ended with a net loss of $13.3M, wider than the previous quarter's $13.2M loss.
Operating cash flow was −$14.7M. Non-cash charges added back $1.4M of depreciation and amortization and $3.9M of share-based compensation. Working capital and other items used $6.7M. Capital expenditures of $463K exceeded it, leaving free cash flow of −$15.2M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $33.5M | +68% | -45.1% | −$13.3M | −$14.7M |
| Q2 2026 | 10-Q | Aug 11, 2026 | $29.4M | +82% | -46.0% | −$13.2M | −$11.3M |
| Q1 2026 | 10-Q | May 8, 2026 | $26.0M | +99% | -47.4% | −$21.3M | −$20.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Alamar Biosciences
Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO™ HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com .
In its own words, from its 8-K, filed Aug 10, 2026.
Alamar Biosciences against its Laboratory Analytical Instruments peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +68% against the peers' median +5%. Operating margin: -45.1% against the peers' median 8.2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ALMR Alamar Biosciences | Q3 2026 | $33.5M | +68% | -45.1% |
| A Agilent Technologies | Q3 FY26 | $1.9B | +8% | 23.6% |
| WAT Waters | Q3 2026 | $1.8B | +121% | 7.2% |
| AVTR Avantor | Q3 2026 | $1.7B | +5% | 8.2% |
| ILMN Illumina | Q3 2026 | $1.1B | +4% | 27.0% |
| MTD Mettler Toledo International | Q3 2026 | $1.1B | +6% | 27.4% |
| BRKR Bruker | Q3 2026 | $874M | +2% | -10.4% |
| RVTY Revvity | Q3 2026 | $729M | +4% | 10.6% |
| BIO Bio-Rad Laboratories | Q3 2026 | $656M | +0.5% | -7.6% |
Source: Alamar Biosciences 10-Q on SEC EDGAR · CIK 2104204 · Laboratory Analytical Instruments
Guidance and outlook
13F: who owns ALMR and who is buying
More on ALMR
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results